Partnering
Partnering
Our partnerships
Zihipp entered into an exclusive license with Imperial College London in February 2019 under which it has exclusive rights to certain clinical and pre-clinical GLP-1 and PYY analogue programmes developed at the College, and an associated portfolio of patents and pending applications
Zihipp also has an exclusive option to further related programmes and the associated data and intellectual property arising in the Department of Metabolic Medicine at Imperial College London